ClinicalTrials.gg
RecruitingNCT07203729Updated Oct 15, 2026

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

A Phase 2 interventional study of Trastuzumab Rezetecan and Chemotherapy of Physician's Choice in HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 2, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 15, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies testing trastuzumab rezetecan in Breast Neoplasms — 46 open to participants now, 52 under way, 10 of them phase 3. trastuzumab rezetecan · Breast Neoplasms.

Planned enrollment
17th of 53
184 · median 111
Started
2026
with 20 others
Phase 2
34 of 53
34 open now
Primary completion
2030-06
later than 47 of 51 live
Registered
30th of 53
by date
Lead sponsor
4 of 53
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Among the 53 studies testing trastuzumab rezetecan in Breast Neoplasms, this one is the 17th largest by planned enrollment, is one of 21 that started in 2026, is one of 34 in phase 2, reaches primary completion later than 47 of the 51 other live ones, and was the 30th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

46 of the 53 studies testing trastuzumab rezetecan in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

40 more — sign in →

By country, each count listing its studies:

All 46 open studies →

Where they have run

About trastuzumab rezetecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing trastuzumab rezetecan in Breast Neoplasms, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if Trastuzumab Rezetecan (SHR-A1811) is safe and tolerable for patients with HER2-Low unresectable/metastatic breast cancer complicated with visceral crisis. Participants will take Trastuzumab Rezetecan every three weeks, until disease progression or intolerable toxicity.

03

Conditions studied

  • HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis

Browse trials for

Keywords

  • HER2-Low unresectable/metastatic breast cancer
  • Visceral Crisis
  • Antibody drug conjugates
  • Trastuzumab Rezetecan
04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: ≥18 years old and ≤75 years old;
  • confirmed -Low unresectable or breast cancer;
  • Investigator-assessed visceral crisis. Visceral crisis includes clinical crisis and molecular crisis. Subjects must meet the criteria for either clinical crisis or molecular crisis.

Clinical crisis is defined as severe organ dysfunction as assessed by signs, symptoms and laboratory studies, resulting from rapid progression of neoplastic disease and indicative of substantial visceral compromise that may serve as an indication for more aggressive therapeutic intervention, including:a)Liver visceral crisis: rapidly increasing >1.5 × in the absence of Gilbert's syndrome or biliary tract obstruction;b)Lung visceral crisis: rapidly increasing dyspnoea at rest, not alleviated by drainage of pleural effusion;c)Other visceral crises: the evaluation is conducted by the clinician based on the definition of visceral crisis specified in the ABC7 guideline.

Molecular crisis is defined as a baseline monocyte-derived cfDNA fraction \< 0.0581, as determined by cell-specific cfDNA methylation analysis of the patient's baseline plasma sample. All patients undergoing screening must provide plasma samples for cfDNA methylation testing.

  • Patients whom investigators deem to have indications for single-agent chemotherapy.
  • Sufficient bone marrow function, defined as follows:a) (ANC) ≥ 1,500/mm³ (1.5 × 10⁹/L);b) count (PLT) ≥ 80 ×10\^9/L;c) (Hb) ≥ 80 g/L;
  • Patients who have received ≤ 3 in the advanced stage are permitted.
  • Patients who have received endocrine therapy in the advanced stage are permitted.
  • Previous treatment with CDK4/6 inhibitors is permitted.
  • Previous or concurrent local treatment for symptom relief is permitted.
  • For female subjects who are premenopausal or not surgically sterilized:

A serum pregnancy test must be performed within 7 days before the first dose of study drug, with a negative result. They must agree to either abstain from sexual activity or use a medically approved highly effective method from the time of signing the form, throughout the study period, and for 1 year after the last dose of study drug.

  • Patients must voluntarily participate in this study, sign the informed consent form, have good compliance, and be willing to cooperate with follow-up.

Exclusion criteria

Exclusion Criteria:

  • Have received treatment with new antibody-drug conjugates (ADCs) at any stage of breast cancer.
  • Are deemed by the investigator as unsuitable for systemic chemotherapy.
  • Have had other malignant tumors within the past 5 years, excluding cured carcinoma in situ of the cervix, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma (patients with other malignant tumors that occurred more than 5 years before randomization and were cured solely by surgery are eligible for enrollment).
  • Have undergone major surgical procedures or suffered significant trauma within 4 weeks prior to randomization, or are expected to undergo major surgical treatment.
  • Have severe heart disease or cardiac discomfort, including but not limited to the following conditions:a) A history of heart failure or systolic dysfunction ( [LVEF] \< 50%);b) High-risk angina pectoris requiring treatment or cardiac arrhythmias;c) valvular heart disease;d) findings indicating transmural myocardial infarction;e) Poorly controlled hypertension.
  • Have a known history of allergy to any component of the drugs in this protocol.
  • Have a history of immunodeficiency, including infection, or other acquired or congenital immunodeficiency diseases.
  • Have a known history of allogeneic organ transplantation or hematopoietic stem cell transplantation.
  • Have a known history of psychotropic substance abuse or drug addiction.
  • Are pregnant or lactating women, or women of childbearing age who are unwilling to use effective measures throughout the trial period and within 7 months after the last administration of the study drug.
  • Have severe diseases, other comorbidities that would interfere with the planned treatment, or any other conditions that make them unsuitable for participation in this study (e.g., active , pulmonary infection requiring treatment).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
184 participants (estimated)

Study arms

  • Experimental
    Arm 1:Trastuzumab Rezetecan

    Drug: Trastuzumab Rezetecan

  • Active comparator
    Arm 2:Chemotherapy of Physician's Choice

    Drug: Chemotherapy of Physician's Choice

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Progression-Free Survival is defined as the time from randomization to first documented disease progression (PD) using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) or death from any cause, whichever occurred first. The PFS will be will be estimated using Kaplan-Meier method. A Kaplan-Meier curve, median PFS, hazard ratio with appropriate confidence intervals will be reported.

    Time frame: From the start of treatment to 36 month

Secondary outcomes

  1. Clinical Benefit Response (CBR)

    CBR is percentage of participants with best (confirmed) PR or CR or SD for at least 6 months. PR or CR or SD is according to RECIST version 1.1. The CBR will be reported by percentage with each arms and appropriate confidence intervals.

    Time frame: From the start of treatment to 36 month

  2. Objective Overall Response Rate (ORR)

    ORR is defined as percentage of participants with best (confirmed) overall response (BOR) of either CR or PR. ORR was assessed by the investigator according to RECIST version 1.1 and is based on BOR, which is defined as best response recorded from start of study treatment until disease progression/recurrence or death. The ORR will be reported by percentage with each arms and appropriate confidence intervals.

    Time frame: From the start of treatment to 36 month

  3. Overall Survival (OS)

    Overall Survival , defined as the time from the start of treatment to the date of death, regardless of the cause of death. The OS will be estimated using Kaplan-Meier method. A Kaplan-Meier curve, median OS, hazard ratio with appropriate confidence intervals will be reported.

    Time frame: From the start of treatment to 36 month

  4. Adverse events (AEs)

    AEs were graded according to the National Cancer Institute's Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0. The type, grade and frequency of AEs will be reported.

    Time frame: From the start of treatment to 36 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2030, 51 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 51 months is close to that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Oct 2, 2025
StartActual
Mar 1, 2026
Primary completionEst.
Jun 15, 2030
CompletionEst.
Dec 30, 2030
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited, 2 added
What changed in the criteria
Inclusion criteria
  • AddedInvestigator-assessed visceral crisis. Visceral crisis includes clinical crisis and molecular crisis. Subjects must meet the criteria for either clinical crisis or molecular crisis.
  • EditedVisceralClinical crisis is defined as severe organ dysfunction as assessed by signs, symptoms and laboratory studies, resulting from rapid progression of neoplastic disease and indicative of substantial visceral compromise that may serve as an indication for more aggressive therapeutic intervention, including:a)Liver visceral crisis: rapidly increasing bilirubin >1.5 × ULN in the absence of Gilbert's syndrome or biliary tract obstruction;b)Lung visceral crisis: rapidly increasing dyspnoea at rest, not alleviated by drainage of pleural effusion;c)Other visceral crises: the evaluation is conducted by the clinician based on the definition of visceral crisis specified in the ABC7 guideline.
  • AddedMolecular crisis is defined as a baseline monocyte-derived cfDNA fraction < 0.0581, as determined by cell-specific cfDNA methylation analysis of the patient's baseline plasma sample. All patients undergoing screening must provide plasma samples for cfDNA methylation testing.
  • EditedPatients who have received ≤ 13 line of chemotherapy in the advanced stage are permitted.
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Eligibility 2 inclusion criteria edited, 2 added
    What changed in the criteria
    Inclusion criteria
    • AddedInvestigator-assessed visceral crisis. Visceral crisis includes clinical crisis and molecular crisis. Subjects must meet the criteria for either clinical crisis or molecular crisis.
    • EditedVisceralClinical crisis is defined as severe organ dysfunction as assessed by signs, symptoms and laboratory studies, resulting from rapid progression of neoplastic disease and indicative of substantial visceral compromise that may serve as an indication for more aggressive therapeutic intervention, including:a)Liver visceral crisis: rapidly increasing bilirubin >1.5 × ULN in the absence of Gilbert's syndrome or biliary tract obstruction;b)Lung visceral crisis: rapidly increasing dyspnoea at rest, not alleviated by drainage of pleural effusion;c)Other visceral crises: the evaluation is conducted by the clinician based on the definition of visceral crisis specified in the ABC7 guideline.
    • AddedMolecular crisis is defined as a baseline monocyte-derived cfDNA fraction < 0.0581, as determined by cell-specific cfDNA methylation analysis of the patient's baseline plasma sample. All patients undergoing screening must provide plasma samples for cfDNA methylation testing.
    • EditedPatients who have received ≤ 13 line of chemotherapy in the advanced stage are permitted.
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07203729
Responsible party
Ma Fei,MD (Chief Physician, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Principal investigator
First posted
Oct 2, 2025
Start date
Mar 1, 2026
Primary completion
Jun 15, 2030 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Oct 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab rezetecan

Start the discussion